Home Health & Wellness Study Uncovers Key Immune Cells That Could Transform Cancer Treatment

Study Uncovers Key Immune Cells That Could Transform Cancer Treatment

Reading Time: 2 minutes

Recent research published in Nature Cancer has shed light on the functional relevance of PD-1 expression in Vδ1+ T cells, highlighting its implications for cancer immunotherapy. This study offers a deeper understanding of how these cells operate within tumour environments, particularly in response to checkpoint inhibition (CPI) therapies.

Checkpoint inhibition therapies, especially those that target programmed cell death protein 1 (PD-1) and its ligand PD-L1, have changed the way that advanced cancers are treated in a big way. These therapies work by reactivating exhausted T cells, enabling them to attack cancer cells. However, despite their effectiveness, only a minority of patients respond favourably to these treatments. This discrepancy has driven researchers to explore the underlying biology of PD-1, not just in traditional αβ T cells but also in γδ T cells, especially the Vδ1+ subset.

The study, which was done by a group of researchers from King’s College London and other places, found that melanoma patients are more likely to respond to anti-PD-1 CPI therapy if they have TRDV1 transcripts, which code for the TCRε chain of Vµ1+ γµ T cells. This is especially important for people who do not have a lot of neoantigens, which suggests that Vµ1+ cells are very important when normal αβ T cell responses are not enough.

Researchers used transcriptomic analysis to find that PD-1+Vε1+ cells have a different way of staying in tissues and surviving than PD-1+CD8+ T cells. When activated through TCR and NKG2D signalling, these Vε1+ cells keep their effector functions. PD-1 engagement can stop these cells from working, but CPI therapy can turn them back on.

Studies done in a lab showed that PD-1+Vε1+ cells from human skin and non-small cell lung cancer (NSCLC) tissues kept working properly. When these cells were stimulated through their TCR or the NKG2D receptor, they made cytokines and showed cytotoxic activity, which suggests they could be useful in the fight against tumours. Notably, PD-1 significantly slowed down these functions, but they could be restored with PD-L1 blockers like atezolizumab.

The study also highlighted that PD-1+Vδ1+ cells express higher levels of genes associated with tissue residency and homing compared to their PD-1− counterparts. This suggests that these cells are well-equipped to persist and function within tumour environments, making them promising targets for adoptive cell transfer (ACT) therapies in solid cancers.

These findings open new avenues for cancer treatment strategies. The study found that PD-1+Vε1+ cells are important in the immune response to tumours, especially those with few mutations. This suggests that these cells could be used as biomarkers to predict how well CPI therapy will work. This could potentially expand the eligibility for immunotherapy to patients who may not have high neoantigen burdens, thereby broadening the scope of effective cancer treatments.

Also, the fact that these cells have more tissue-resident genes suggests that they might be able to get around the problems of poor tumour homing and persistence that make ACT less effective in solid tumours right now. Future clinical trials focusing on Vδ1+ ACTs could benefit from these insights, improving therapeutic outcomes for patients with various types of cancer.

© Copyright 2014–2034 Psychreg Ltd